DrugPatentWatch Database Preview

Cubist Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for CUBIST PHARMS, and what generic alternatives to CUBIST PHARMS drugs are available?

CUBIST PHARMS has six approved drugs.

There are twenty-two US patents protecting CUBIST PHARMS drugs.

There are two hundred and sixty-three patent family members on CUBIST PHARMS drugs in forty-three countries and thirty-nine supplementary protection certificates in thirteen countries.

Summary for Cubist Pharms

International Patents:	263
US Patents:	22
Tradenames:	6
Ingredients:	5
NDAs:	6

Drugs and US Patents for Cubist Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011		RX	Yes	Yes	8,859,510
Cubist Pharms	ENTEREG	alvimopan	CAPSULE;ORAL	021775-001	May 20, 2008		RX	Yes	Yes	6,469,030
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	TABLET;ORAL	205435-001	Jun 20, 2014		RX	Yes	Yes	7,816,379		Y	Y
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;IV (INFUSION)	021572-001	Sep 12, 2003		DISCN	No	No
Cubist Pharms	ENTEREG	alvimopan	CAPSULE;ORAL	021775-001	May 20, 2008		RX	Yes	Yes	8,112,290				Y
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	AP	RX	Yes	Yes
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	AP	RX	Yes	Yes

Expired US Patents for Cubist Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;IV (INFUSION)	021572-001	Sep 12, 2003	RE39071
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	RE39071
Cubist Pharms	ENTEREG	alvimopan	CAPSULE;ORAL	021775-001	May 20, 2008	5,250,542
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;IV (INFUSION)	021572-001	Sep 12, 2003	5,912,226
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	5,912,226
Cubist Pharms	ENTEREG	alvimopan	CAPSULE;ORAL	021775-001	May 20, 2008	5,434,171

Paragraph IV (Patent) Challenges for CUBIST PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	For Injection	500 mg/vial		2008-11-19
	Capsules	12 mg		2017-06-16
	Tablets	200 mg		2015-05-27

International Patents for Cubist Pharms Drugs

Country	Document Number	Estimated Expiration
Lithuania	C1699784
Canada	2906151
Australia	2003274754
Russian Federation	2011136537
Hungary	E027757
Costa Rica	20110464
Ecuador	SP12011939

Supplementary Protection Certificates for Cubist Pharms Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539977/01	Switzerland		PRODUCT NAME: FIDAXOMICIN; REGISTRATION NO/DATE: SWISSMEDIC 62957 01.05.2014
C0062	France		PRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325
C/GB06/024	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021.
90047-5	Sweden		PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
2015000078	Germany		PRODUCT NAME: TEDIZOLID, GEGEBENENFALLS IN FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/991/001-003 20150323
2006 00018	Denmark		PRODUCT NAME: DAPTOMYCIN
/2006	Austria		PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cubist Pharms
• Cubist Pharms Llc